1. Home
  2. MITQ vs LYRA Comparison

MITQ vs LYRA Comparison

Compare MITQ & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

N/A

Current Price

$0.55

Market Cap

5.7M

ML Signal

N/A

Logo Lyra Therapeutics Inc.

LYRA

Lyra Therapeutics Inc.

HOLD

Current Price

$1.32

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MITQ
LYRA
Founded
N/A
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical/Dental Instruments
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
5.6M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
MITQ
LYRA
Price
$0.55
$1.32
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
25.2K
64.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$20,139,000.00
$1,534,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$57.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.08
52 Week High
$1.66
$37.50

Technical Indicators

Market Signals
Indicator
MITQ
LYRA
Relative Strength Index (RSI) 36.88 40.29
Support Level $0.51 $1.21
Resistance Level $0.80 $1.52
Average True Range (ATR) 0.06 0.15
MACD 0.00 0.06
Stochastic Oscillator 55.05 72.12

Price Performance

Historical Comparison
MITQ
LYRA

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: